MarketPulse

Rule 10b5-1 trading plan

22 articles
The Motley FoolThe Motley Fool··Sarah Sidlow

Maze Therapeutics CSBO Sells $190K in Stock Despite Strong Trial Data

Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.
MAZEclinical-stage biotechprecision medicine
The Motley FoolThe Motley Fool··Robert Izquierdo

Adaptive Biotech COO Sells $271K in Stock, But Company's Growth Story Remains Intact

Adaptive Biotechnologies COO Julie Rubinstein sold 19,037 shares worth $271,000 under a pre-planned trading arrangement, retaining substantial equity as the biotech firm posts strong 55% revenue growth.
ADPToperating lossesrevenue growth
The Motley FoolThe Motley Fool··Sarah Sidlow

Pacira CFO Offloads $326K in Stock Ahead of Strong Q1 Results

Pacira CFO sold $326K in stock via pre-planned trading arrangement before Q1 earnings beat, with shares appreciating 12% in April.
PCRXQ1 earningspharmaceutical company
The Motley FoolThe Motley Fool··Robert Izquierdo

Iradimed CEO Dumps $694K in Stock—Here's Why Investors Shouldn't Panic

Iradimed CEO sells $694K in shares via pre-planned strategy while retaining 4M+ shares. Strong 78% stock gain reflects 14% revenue growth, but 42x forward P/E suggests patience before buying.
IRMDstock valuationearnings growth
The Motley FoolThe Motley Fool··Robert Izquierdo

Pitney Bowes CEO Offloads $2.2M in Stock via Planned Sale

Pitney Bowes CEO sells $2.2M in stock via pre-planned transaction while retaining 8M shares, as company posts $145M profit swing and 24% free cash flow growth despite 7% revenue decline.
PBIPBIpBfree cash flowdividend yield
The Motley FoolThe Motley Fool··Robert Izquierdo

Maze CMO Dumps Entire Stock Position as Biotech Faces Clinical Uncertainty

Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.
MAZEFDA approvalkidney disease
The Motley FoolThe Motley Fool··Seena Hassouna

Immunome Insider Sale Masks Real Story: FDA Filing Looms for Varegacestat

Immunome's Chief Scientific Officer trimmed his stake by 30%, but the real catalyst is varegacestat's planned Q2 2026 FDA submission following positive Phase 3 trial results.
IMNMPhase 3 trialNDA submission
The Motley FoolThe Motley Fool··Robert Izquierdo

RingCentral CAO Sells $360K in Shares, but Pre-Planned Trade Signals No Major Concern

RingCentral's CAO sold $360K in shares via pre-planned trading agreement, retaining 75K+ shares, signaling no distress amid strong 2025 performance.
RNGvaluationprofitability
The Motley FoolThe Motley Fool··Cory Renauer

Liquidia CCO Liquidates $2.8M Stock Position Amid Strong Product Sales Growth

Liquidia's Chief Commercial Officer sold 80,000 shares worth $2.8M through pre-arranged plan while retaining substantial holdings as flagship product Yutrepia drives record quarterly profits.
LQDAbiotechnologyinsider sale
The Motley FoolThe Motley Fool··Jonathan Ponciano

Adaptive Biotech COO Sells $2.4M in Stock as Revenue Surges 55% YoY

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.
ADPTrevenue growthEBITDA
The Motley FoolThe Motley Fool··Robert Izquierdo

C3.ai Executive Chairman Dumps $4.4M in Shares Amid Stock Decline and Leadership Turmoil

C3.ai executive chairman sold $4.4M in shares via pre-planned trading arrangement amid 46% revenue decline and CEO transition.
AIstock valuationrevenue decline
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.
MAZEclinical-stage biotechearnings report
The Motley FoolThe Motley Fool··Robert Izquierdo

Dave Director Dumps $6.4M in Stock: Strong Fundamentals Clash With Insider Selling

Dave board member sells $6.4M in stock despite 60% revenue growth and strong 2025 earnings, creating mixed signals for investors evaluating the fintech firm's buy-or-sell case.
DAVEDAVEWfintechstock valuation
The Motley FoolThe Motley Fool··Robert Izquierdo

Fastly CEO Offloads $1.2M in Stock as AI Boom Pushes Valuation to Extremes

Fastly CEO sells $1.2M in stock via pre-planned trading program. Stock surged 265.5% on AI boom but trades at multi-year valuation high.
FSLYinsider tradingvaluation concerns
The Motley FoolThe Motley Fool··Robert Izquierdo

Freshworks Insider Sell-Off Masks Bullish Fundamentals as Stock Eyes Recovery

Freshworks executive sells $275K in shares via pre-planned trading program, but analyst maintains buy rating citing 16% revenue growth and improving profitability.
FRSHvaluationstock price decline
The Motley FoolThe Motley Fool··Robert Izquierdo

Clear Secure Director's $1.5M Stock Sale Raises Valuation Questions Despite Growth

Clear Secure director sold 33,000 shares worth $1.5M via pre-planned trading arrangement. Stock up 117.7% yearly, but elevated P/E of 29 prompts caution.
YOUvaluationrevenue growth
The Motley FoolThe Motley Fool··Adé Hennis

UWMC Chief Executes $9M Share Divestment as Holdings Drop Nearly Half

UWMC CEO Mat Ishbia sold 1.9M shares for $9M, cutting his holdings nearly in half. The pre-arranged sale reflects ongoing pressure on the mortgage lender's stock.
UWMCearnings reportinsider sale
The Motley FoolThe Motley Fool··Robert Izquierdo

Novanta CEO Share Sale Reflects Valuation Concerns Despite Strong Growth Momentum

Novanta CEO sells shares in routine plan sale. Stock up 23% YTD with strong growth, but elevated valuation concerns limit upside potential.
NOVTNOVTUvaluationinsider trading
The Motley FoolThe Motley Fool··Adé Hennis

Phibro CEO Divests $3.74M in Stock Following Robust Second-Quarter Results

Phibro CEO Jack Bendheim sold $3.74M in stock via pre-planned trading agreement following strong Q2 results driven by expanded product portfolio and strategic acquisitions.
PAHCearnings growthinsider trading
The Motley FoolThe Motley Fool··Robert Izquierdo

SentinelOne CEO Executes Scheduled Share Sale Amid Stock Decline

SentinelOne CEO sold $532K in shares via pre-arranged plan amid 43% stock decline. Stock trades at attractive valuations as company approaches $1B revenue milestone.
Svaluationstock price decline